Abstract 2111P
Background
Psychometric assessment tools are widely available but underutilized in daily oncology practice. The aim of this study was to evaluate the role of multiple psychometric scales in identifying cancer patients in distress who need Psycho-Oncology management.
Methods
Colorectal cancer patients were prospectively asked to complete a survey including 3 psychometric scales (GAD-7, PHQ-9, PC-PTSD-5). Those scoring high on at least one scale (GAD-7 score ≥ 10, PHQ-9 score ≥ 10, PC-PTSD-5 score ≥ 4) were offered referral to the Psycho-Oncology service. Those accepting the referral were further triaged by members of this service via a standardized semi-structured interview. Patients were divided into three groups: those accepted by the Psycho-Oncology service, those declined the referral and those discharged from the service with no need for further intervention. Outcomes were compared with the analysis of variance test (ANOVA).
Results
Fifty-four patients (30 females) of median age 60 years (range 36-81) were prospectively evaluated. 20 patients (37%) reported their cancer was under control, 15 (28%) believed they had progressive disease, while 19 (35%) were uncertain. Approximately half patients (26; 48%) referred a prior history of a mental condition. The mean (±SE) scores for each psychometric scale were 10.96 (± 0.78), 12.79 (± 0.82), and 1.07 (± 0.21), respectively for GAD-7, PHQ-9, PC-PTSD-5. Thirty-four patients (63%) scored high on GAD-7, 40 (74%) on PHQ-9 and 8 (15%) on PC-PTSD-5. Almost half of the patients declined a referral (25, 46%), 22 (41%) were assessed by a Psycho-Oncologist and managed accordingly and 7 (13%) were discharged after the initial tirage. There was no statistically significant difference in the mean psychometric scores between the three identified groups (p<0.05).
Conclusions
Psychometric scales are useful screening tools to identify distress but cannot differentiate between general distress and psychological/psychiatric symptoms requiring specialist intervention. Psychometric scales should be used in conjunction with semi-structured interviews. The ‘screen and triage’ model should be further investigated as part of an integrated care model, to signpost cancer patients to appropriate support services.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Servier.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2028TiP - Phase I, non-randomised, open-label, multi-centre dose escalation trial of BI 764532 (DLL3/CD3 IgG-like T cell engager [TcE]) + ezabenlimab (anti-PD-1 antibody) in patients (pts) with small cell lung cancer (SCLC) and other neuroendocrine carcinomas (NECs) expressing DLL3
Presenter: Julien Mazieres
Session: Poster session 06
2029TiP - Phase I study of ABBV-706, an anti-SEZ6 antibody-drug conjugate, alone or in combination in adults with advanced solid tumors
Presenter: Sreenivasa Chandana
Session: Poster session 06
2035P - Routine biomarker monitoring does not replace comprehensive clinical assessment in the detection of immunotherapy induced myocarditis
Presenter: Alexandra Johnson
Session: Poster session 06
2036P - Prevalence and risk evaluation of cardiovascular disease among newly diagnosed prostate cancer population in China
Presenter: Weiyu Zhang
Session: Poster session 06
2037P - Prehabilitation as a strategy to improve postoperative outcomes in frail cancer patients undergoing elective surgery: A systematic review and meta-analysis
Presenter: Muhammed Elfaituri
Session: Poster session 06
2039P - Primary endpoints of confirmatory randomized controlled trials for older patients with cancer: A scoping review
Presenter: Tomonori Mizutani
Session: Poster session 06
2041P - The prevalence of hematologic adverse events (HAEs) and myelodysplastic syndrome/acute myeloid leukemia (MDS/AML) in patients (pts) with advanced high grade ovarian carcinoma (aHGOC) receiving PARP inhibitor (PARPi), with or without a germline BRCA pathogenic variant
Presenter: Carmine Valenza
Session: Poster session 06
2042P - Improving breast cancer outcomes for indigenous women
Presenter: Vita Christie
Session: Poster session 06
2043P - Can Charlson Comorbidity Index (CCI) and Clinical Frailty Scale (CFS) assessments predict survival in octogenarians with colorectal cancer?
Presenter: Neda Nikolic
Session: Poster session 06
2044P - Bloodstream infections (BSI) in cancer patients: Epidemiology, antibiotic therapy and risk factors related to mortality
Presenter: Carlos López Jiménez
Session: Poster session 06